European Archives - Page 576 of 1194 - European Medical Journal

Patients with Hepatitis C Treated with Antivirals Less Likely to be Hospitalised in Future

2.4 million people are living with hepatitis C in the United States, according to federal data, and many don’t know they have the virus…

3D Planning in Paediatric Liver Transplants Associated with Lower Risk of Complications

A study has emerged with interesting risk insights to do with personalisation of treatment in paediatric liver transplantation…

Does Azithromycin Reduce Post-RSV Recurrent Wheeze in Infants?

RESPIRATORY syncytial virus (RSV) is a major cause of lower respiratory disease and hospitalisation in infants worldwide…

Extracorporeal Membrane Oxygenation in Patients with Severe COVID-19

Severe COVID-19 can lead to acute respiratory failure. In patients for whom conventional mechanical ventilatory support has failed, ECMO may be used…

Healthcare in Warzones: Ukraine

This week, Jonathan focuses on the ongoing conflict in Ukraine, discussing the disastrous impacts of war, from environmental consequences to effects on healthcare systems.

Claire Skentelbery, Director General, EuropaBio

Bonus episode this week for GOLD podcast, featuring a full feature-length interview with Claire Skentelbery, Director General, EuropaBio. Stream now!

FDA approves first-in-class cancer checkpoint inhibitor

A new type of checkpoint inhibitor to treat unresectable or metastatic melanoma has been approved by the FDA.

Industry welcomes UK-wide commitment to genomic research

Better genomic testing and access to clinical trials have been prioritised and agreed by the UK government and devolved administrations. Read for more details.

The risks, rewards and future potential of biotechnology

In this episode, Marc and Helena have a chat about biotech with special guest Claire Skentelbery, Director General of EuropaBio.

Targeting the Immune System and Beyond: The Potential for Safe and Durable Responses in Higher-Risk Myelodysplastic Syndromes with Immuno-Myeloid Therapy

The hypomethylating agents (HMA), azacitidine and decitabine, are currently regarded as the standard of care for patients with…